Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Activated human lymphocytes secrete a soluble factor that aggregates leukocytes.

B Rouveix, F Groult, M Levacher

    Cellular Immunology
    |May 1, 1986
    PubMed
    Summary

    Researchers identified a soluble factor, leukocyte aggregating factor (LAgF), produced by stimulated lymphocytes that causes human leukocyte aggregation. This protein factor has specific molecular and charge properties, suggesting a role in inflammatory processes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Current state of resistance of E. coli to trimethoprim in uncomplicated urinary tract infections in France].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2019
    Same author

    [Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci].

    Medecine et maladies infectieuses·2012
    Same author

    Clinical implications of multiple drug resistance efflux pumps of pathogenic bacteria.

    The Journal of antimicrobial chemotherapy·2007
    Same author

    [Clinically significant toxicity and tolerance of the main antibiotics used in lower respiratory tract infections].

    Medecine et maladies infectieuses·2006
    Same author

    Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells.

    Rheumatology (Oxford, England)·2001
    Same author

    Classification of oral cephalosporins. A matter for debate.

    International journal of antimicrobial agents·2001

    Area of Science:

    • Immunology
    • Cell Biology
    • Biochemistry

    Background:

    • Human polymorphonuclear leukocytes aggregate in response to inflammatory stimuli, a process implicated in pathogenesis.
    • Lymphocytes produce soluble factors that can modulate leukocyte behavior.

    Purpose of the Study:

    • To identify and characterize a soluble factor from concanavalin A-stimulated lymphocytes that induces human leukocyte aggregation.
    • To determine the biochemical properties of this leukocyte aggregating factor (LAgF).

    Main Methods:

    • Lymphocytes were stimulated with concanavalin A, and the supernatant was collected.
    • Leukocyte aggregation was quantified using spectrophotometry measuring light absorbance.
    • LAgF was characterized using Sephadex G-100 gel filtration, chromatofocusing, and enzymatic/chemical treatments.

    Related Experiment Videos

    Main Results:

    • A lymphokine, termed leukocyte aggregating factor (LAgF), was identified, with maximum release at 48 hours.
    • LAgF exhibited a molecular weight range of 40,000-65,000 and a pI of 5.2.
    • LAgF is a heat-sensitive protein, inactivated by chymotrypsin but not neuraminidase, and partially precipitated by perchloric acid.

    Conclusions:

    • Leukocyte aggregating factor (LAgF) is a protein produced by stimulated lymphocytes that induces human leukocyte aggregation.
    • LAgF's properties suggest it may be identical to leukocyte inhibiting factor (LIF) based on size and physiological characteristics.